The Scottish Medicines Consortium advises NHS Scotland on the clinical and cost-effectiveness of new medicines. Recent process changes have given patients and clinicians a stronger voice in decisions for end of life and orphan medicines. Thematic analysis of information provided by patients and carers has improved our understanding of the key factors that are important to patients.
|Publication status||Published - 10 May 2016|
|Event||HTAi 2016 Annual Meeting : Informing Health Care Decisions with Values and Evidence - Keio Plaza Hotel, Tokyo, Japan|
Duration: 10 May 2016 → 14 May 2016
http://meeting.htai.org/events/tokyo2016/event-summary-4023afce0ec04ab387500e87f0a6a42d.aspx (Conference website)
|Conference||HTAi 2016 Annual Meeting|
|Abbreviated title||HTAi 2016|
|Period||10/05/16 → 14/05/16|
Jones, J., Harkess-Murphy, E., Lockhart, L., Lee, A., Fox, J., & Brown, A. (2016). Added value of end of life and orphan medicines: a thematic analysis from the patient/carer perspective. Poster session presented at HTAi 2016 Annual Meeting , Tokyo, Japan.